Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind vehicle-controlled study of OT202 eye drops in moderate to severe dry eye disease
CTR20262720Phase 3Active
- Sponsor
- Ocumension Biotech
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of OT-202 in dry eye syndrome (DED), sponsored by Ocumension Biotech. Started Jul 2026; status: active.
02
Drugs
OT-202
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on CTR20262720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262720.